Spyre Therapeutics Inc. is focused on advancing innovative therapies for Inflammatory Bowel Disease (IBD) through the development of next-generation monoclonal antibodies and rational therapeutic combinations. Their pipeline includes several promising candidates, such as SPY001, which targets the α4β7 integrin, and SPY002 and SPY003, which are designed to bind to TL1A and IL-23, respectively. These antibodies are characterized by their high potency, selectivity, and extended half-lives, aiming to enhance treatment efficacy and patient convenience. The company is committed to exploring both monotherapies and combination therapies that could redefine treatment paradigms for IBD.

In addition to their focus on individual antibody development, Spyre Therapeutics is dedicated to precision immunology approaches that seek to improve dosing and overall treatment outcomes. Their strategy includes investigating combinations of their lead candidates, such as pairing α4β7 with TL1A or IL-23, to potentially create synergistic effects that could lead to more effective therapies. By leveraging their team's extensive experience in drug development and commercialization, Spyre aims to deliver best-in-class treatment options that address the unmet needs of patients suffering from IBD.

United States

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

Digestive System Diseases

Spyre Therapeutics Inc

Crohns disease

Inflammatory bowel disease

SPY001 (α4β7)

Ulcerative colitis

SPY002 (SPY002-091) (TL1A)

Axial spondyloarthritis

Psoriatic arthritis

Rheumatoid arthritis

SPY072 (SPY002-072)

SPY003 is an investigational, novel, extended half-life monoclonal antibody targeting IL-23, being developed for the potential treatment of IBD. IBD is a chronic condition characterized by inflammation in the gastrointestinal tract and encompasses two main disorders: ulcerative colitis and Crohn's disease.

Spyre Therapeutics Inc

Company Details